Luc Desnoyers

TL;DR: In this paper, the present invention is directed to secreted and transmembrane polypeptides and to nucleic acid molecules encoding those polyptides, and vectors and host cells comprising those nucleic amino acid sequences.

TL;DR: KLB is defined as a novel FGFR4 coreceptor required for FGF19 liver specific functions, and is shown to be widely distributed in mouse, whereas KLB distribution is more restricted.

TL;DR: It is reported that fibroblast growth factor 19 and its cognate receptor FGF receptor 4 are coexpressed in primary human liver, lung and colon tumors and in a subset of human colon cancer cell lines, and an anti-FGF19 monoclonal antibody is developed that selectively blocks the interaction of FGF19 with FGFR4.

TL;DR: It is demonstrated that FGFR4 is required for hepatocarcinogenesis; the progeny of FGF19 transgenic mice, which have previously been shown to develop HCCs, bred withFGFR4 knockout mice fail to develop liver tumors and are suggested to be an important and novel therapeutic target in treating this disease.

TL;DR: The data demonstrate that WISP-1 is an osteogenic potentiating factor promoting mesenchymal cell proliferation and osteoblastic differentiation while repressing chondrocytic differentiation and propose that it plays an important regulatory role during bone development and fracture repair.